Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;51(9):3434-6.
doi: 10.1128/AAC.01567-06. Epub 2007 Jul 2.

In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection

Charles J Gill  1 , George K Abruzzo, Amy M Flattery, Andrew S Misura, Ken Bartizal, Emily J Hickey
Affiliations

In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection

Charles J Gill et al. Antimicrob Agents Chemother. 2007 Sep.

Abstract

A novel oxazolidinone, AM 7359, was evaluated in two mouse models of Staphylococcus aureus infection. AM 7359 and linezolid were equally efficacious in a methicillin-susceptible S. aureus organ burden model and a methicillin-resistant S. aureus localized infection model. However, AM 7359 was eightfold more efficacious than linezolid against a linezolid- and methicillin-resistant S. aureus strain in this localized (thigh) infection model.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Efficacy of AM 7359 and linezolid (Lin) against an MRSA COL strain in a localized infection model. DBA/2 mice (five per group) were challenged intramuscularly with 3.6 × 108 CFU of MRSA in a 0.2-ml inoculum and treated p.o. three times a day for 1 day and once a day for 5 days or i.v. three times a day for 1 day and once a day for 1 day.
FIG. 2.
FIG. 2.
Efficacy of AM 7359 and linezolid against an LMRSA strain in a localized infection model. C3H mice (five per group) were challenged intramuscularly with 109 CFU of LMRSA in a 0.2-ml inoculum and treated p.o. three times a day for 1 day and once a day for 5 days.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489. - PMC - PubMed
    1. Attassi, K., E. Hershberger, R. Alam, and M. J. Zervos. 2002. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34:695-698. - PubMed
    1. Auckland, C., L. Teare, F. Cooke, M. E. Kaufman, M. Warner, G. Jones, K. Bamford, H. Ayles, and A. P. Johnson. 2002. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50:743-746. - PubMed
    1. Clinical and Laboratory Standards Institute. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-45(20). Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Craig, W. A. 1996. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 25:213-217. - PubMed